Evergreen Capital Management LLC Acquires 163,439 Shares of Pfizer Inc. (NYSE:PFE)

Evergreen Capital Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 50.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 486,702 shares of the biopharmaceutical company’s stock after acquiring an additional 163,439 shares during the period. Evergreen Capital Management LLC’s holdings in Pfizer were worth $12,912,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer in the 4th quarter valued at $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.5 %

Shares of PFE stock opened at $22.45 on Wednesday. The company has a market cap of $127.30 billion, a P/E ratio of 15.92, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock has a 50 day simple moving average of $25.09 and a two-hundred day simple moving average of $26.31. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, UBS Group lowered their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.